Most Recent Articles about TEVA
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 http://www.zacks.com/stock/news/730536/jazz-jazz-submits-nda-for-xyrem-follow-on-candidate-jzp-258?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-730536 Jan 23, 2020 - Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Why Long-Term Investors Should Avoid TEVA Stock Like the Plague https://www.fool.com/investing/2020/01/22/why-long-term-investors-should-avoid-teva-stock-li.aspx?source=iedfolrf0000001 Jan 22, 2020 - Strapped with debt and battling legal controversies right and left, Teva’s best days could very well be behind it.
Why You Should Still Buy Teva https://seekingalpha.com/article/4318277-why-you-should-still-buy-teva?source=feed_tag_israel Jan 22, 2020 - Teva is set to hold the $10 support line.Company's restructuring and debt reduction on schedule.Future growth in place with two products leading it.

Related Companies

Name Exchange Price Mkt Cap
ALXN Alexion Pharmaceuticals, Inc. NASDAQ $117.77 $26.25B
MYL Mylan N.V. NASDAQ $37.22 $19.19B
BMRN BioMarin Pharmaceutical Inc. NASDAQ $98.11 $17.42B
GRFS Grifols, S.A. NASDAQ $20.42 $13.96B
SRPT Sarepta Therapeutics, Inc. NASDAQ $152.52 $10.13B
Sector: Health Care > Industry: Major Pharmaceuticals